Uterine cancer treatments

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

1 . A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient an effective amount of an antibody specifically binding to an MHC class I or II molecule complexed with an HLA-restricted antigen consisting of the amino acid sequence selected from SEQ ID NO: 12, SEQ ID NO: 13, from SEQ ID NO: 1 to SEQ ID NO: 11, and from SEQ ID NO: 14 to SEQ ID NO: 71,
 wherein said cancer is selected from uterine cancer, acute myelogenous leukemia (AML), breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia (CLL), colorectal carcinoma, esophageal cancer, gallbladder cancer, gastric cancer, hepatocellular cancer (HCC), Merkel cell carcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small cell lung cancer (SCLC), and urinary bladder cancer.   
     
     
         2 . The method of  claim 1 , wherein the antibody is a polyclonal antibody, a monoclonal antibody, or a chimeric antibody. 
     
     
         3 . The method of  claim 1 , wherein the antibody binds to the HLA-restricted antigen with a binding affinity of below 20 nanomolar. 
     
     
         4 . The method of  claim 1 , wherein the antibody binds to the MHC class I molecule complexed with the HLA-restricted antigen. 
     
     
         5 . The method of  claim 1 , wherein the antibody is humanized. 
     
     
         6 . The method of  claim 1 , wherein the effective amount of the antibody is from about 1 μg/kg to about 100 mg/kg of body weight per day. 
     
     
         7 . The method of  claim 1 , wherein the antibody is conjugated with a toxin. 
     
     
         8 . The method of  claim 1 , wherein the antibody is conjugated with an immune stimulating domain. 
     
     
         9 . The method of  claim 1 , wherein the cancer is uterine cancer. 
     
     
         10 . The method of  claim 1 , wherein the cancer is AML. 
     
     
         11 . The method of  claim 1 , wherein the cancer is breast cancer. 
     
     
         12 . The method of  claim 1 , wherein the cancer is pancreatic cancer. 
     
     
         13 . The method of  claim 1 , wherein the cancer is brain cancer. 
     
     
         14 . The method of  claim 1 , wherein the cancer is prostate cancer. 
     
     
         15 . The method of  claim 1 , wherein the cancer is colorectal carcinoma. 
     
     
         16 . The method of  claim 1 , wherein the cancer is ovarian cancer. 
     
     
         17 . The method of  claim 1 , wherein the cancer is non-Hodgkin lymphoma. 
     
     
         18 . The method of  claim 1 , wherein the cancer is melanoma. 
     
     
         19 . The method of  claim 1 , wherein the cancer is HCC. 
     
     
         20 . The method of  claim 1 , wherein the cancer is NSCLC.